GLP TOXICOLOGY TESTING AND PHASE 2/3 DEVELOPMENT FOR A NONOPIOID, INJECTABLE DRUG PRODUCT FOR THE TREATMENT OF LUMBOSACRAL RADICULOPATHY (SCIATICA)
$4,970,751FY2021Defense Health AgencyDOD
Spinethera Inc
Investigators
View source on USAspending →GLP TOXICOLOGY TESTING AND PHASE 2/3 DEVELOPMENT FOR A NONOPIOID, INJECTABLE DRUG PRODUCT FOR THE TREATMENT OF LUMBOSACRAL RADICULOPATHY (SCIATICA) · GrantIndex